An Experimental Human Colonization Model with Pneumococcal Serotype 3 has the Potential to be Used for Vaccine Studies.
作者信息
Henriques-Normark Birgitta, Narciso Ana Rita
机构信息
Department of Microbiology, Tumor and Cell Biology.
Department of Clinical Microbiology Karolinska University Hospital Stockholm, Sweden.
出版信息
Am J Respir Crit Care Med. 2022 Dec 1;206(11):1312-1314. doi: 10.1164/rccm.202207-1342ED.
Abstract
摘要
相似文献
1
An Experimental Human Colonization Model with Pneumococcal Serotype 3 has the Potential to be Used for Vaccine Studies.
Am J Respir Crit Care Med. 2022 Dec 1;206(11):1312-1314. doi: 10.1164/rccm.202207-1342ED.
2
Intranasal Immunization with the Commensal Confers Protective Immunity against Pneumococcal Lung Infection.
Appl Environ Microbiol. 2019 Mar 6;85(6). doi: 10.1128/AEM.02235-18. Print 2019 Mar 15.
3
Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).
Vaccine. 2019 Aug 23;37(36):5466-5473. doi: 10.1016/j.vaccine.2019.05.003. Epub 2019 Jul 23.
4
Heptavalent pneumococcal vaccine conjugated to outer membrane protein of Neisseria meningitidis serogroup b and nasopharyngeal carriage of Streptococcus pneumoniae in infants.
Vaccine. 2003 Jun 2;21(19-20):2627-31. doi: 10.1016/s0264-410x(03)00039-2.
5
Commentary on paradoxical observations pertaining to the impact of the 13-valent pneumococcal conjugate vaccine on serotype 3 Streptococcus pneumoniae infections in children.
Vaccine. 2018 Sep 5;36(37):5495-5496. doi: 10.1016/j.vaccine.2018.07.069. Epub 2018 Aug 1.
6
Pneumococcal immunization with conjugate vaccines: are 10-valent and 13-valent vaccines similar?
Future Microbiol. 2019 Jul;14:921-923. doi: 10.2217/fmb-2019-0151. Epub 2019 Aug 2.
7
Impact of the pneumococcal conjugate vaccine on serotype distribution and susceptibility trends of pediatric non-invasive Streptococcus pneumoniae isolates in Tokai, Japan over a 5-year period.
J Infect Chemother. 2014 Jul;20(7):423-8. doi: 10.1016/j.jiac.2014.03.010. Epub 2014 May 5.
8
Characteristics of Streptococcus pneumoniae serotype 19A isolates from children in the pre and post Conjugate Vaccine Era. Single center experience 1986-2015.
Vaccine. 2018 Aug 23;36(35):5245-5250. doi: 10.1016/j.vaccine.2018.07.055. Epub 2018 Jul 27.
9
Long-term effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae in children in Brazil.
Vaccine. 2019 Aug 23;37(36):5357-5363. doi: 10.1016/j.vaccine.2019.07.043. Epub 2019 Jul 24.
10
PCR-based discrimination of emerging Streptococcus pneumoniae serotypes 22F and 33F.
J Microbiol Methods. 2018 Jan;144:99-106. doi: 10.1016/j.mimet.2017.11.017. Epub 2017 Nov 21.
本文引用的文献
1
Human Infection Challenge with Serotype 3 Pneumococcus.
Am J Respir Crit Care Med. 2022 Dec 1;206(11):1379-1392. doi: 10.1164/rccm.202112-2700OC.
2
Sugar-Coated Killer: Serotype 3 Pneumococcal Disease.
Front Cell Infect Microbiol. 2020 Dec 23;10:613287. doi: 10.3389/fcimb.2020.613287. eCollection 2020.
3
A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large Fragment from an Oral Streptococcus.
mBio. 2020 May 19;11(3):e00937-20. doi: 10.1128/mBio.00937-20.
4
Evolution of Serotype 3 in England and Wales: A Major Vaccine Evader.
Genes (Basel). 2019 Oct 25;10(11):845. doi: 10.3390/genes10110845.
5
Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
Vaccine. 2019 Jul 26;37(32):4491-4498. doi: 10.1016/j.vaccine.2019.06.071. Epub 2019 Jul 2.
6
Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations.
Clin Infect Dis. 2017 Nov 13;65(11):1780-1789. doi: 10.1093/cid/cix685.
7
Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study.
Lancet Respir Med. 2017 Aug;5(8):648-656. doi: 10.1016/S2213-2600(17)30110-8. Epub 2017 Mar 27.
8
Serotype 3 Remains the Leading Cause of Invasive Pneumococcal Disease in Adults in Portugal (2012-2014) Despite Continued Reductions in Other 13-Valent Conjugate Vaccine Serotypes.
Front Microbiol. 2016 Oct 14;7:1616. doi: 10.3389/fmicb.2016.01616. eCollection 2016.
9
Unaltered pneumococcal carriage prevalence due to expansion of non-vaccine types of low invasive potential 8years after vaccine introduction in Stockholm, Sweden.
Vaccine. 2016 Aug 31;34(38):4565-4571. doi: 10.1016/j.vaccine.2016.07.031. Epub 2016 Jul 26.
10
Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.
Eur Respir J. 2016 Apr;47(4):1208-18. doi: 10.1183/13993003.01451-2015. Epub 2016 Jan 21.
Zotero 插件